Endo International PLC (ENDP)

ENDP (NASDAQ:Drugs) EQUITY
$15.44
pos +0.28
+1.80%
Today's Range: 14.78 - 15.61 | ENDP Avg Daily Volume: 9,594,600
Last Update: 05/24/16 - 3:59 PM EDT
Volume: 6,935,671
YTD Performance: -75.25%
Open: $15.33
Previous Close: $15.16
52 Week Range: $12.56 - $88.54
Oustanding Shares: 222,661,344
Market Cap: 3,437,891,151
6-Month Chart
TheStreet Ratings Grade for ENDP
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 5 6 6 7
Moderate Buy 1 1 1 0
Hold 10 8 8 7
Moderate Sell 0 0 0 0
Strong Sell 1 0 0 0
Mean Rec. 2.47 2.13 2.13 2.00
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 4.54
Price Earnings Comparisons:
ENDP Sector Avg. S&P 500
4.54 0.00 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-69.82% -82.15% -55.79%
GROWTH 12 Mo 3 Yr CAGR
Revenue 13.60 0.10 0.03
Net Income 0.00 -0.60 0.00
EPS 0.00 0.20 0.00
Earnings for ENDP:
EBITDA 1.01B
Revenue 3.27B
Average Earnings Estimates
Qtr (06/16) Qtr (09/16) FY (12/16) FY (12/17)
Average Estimate $0.92 $1.16 $4.59 $5.23
Number of Analysts 10 10 11 12
High Estimate $1.36 $1.52 $4.66 $6.75
Low Estimate $0.72 $0.94 $4.51 $4.55
Prior Year $1.08 $1.02 $4.87 $4.59
Growth Rate (Year over Year) -14.91% 13.33% -5.81% 14.03%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
By

David Katz

 | May 12, 2016 | 8:00 AM EDT

Despite an earnings beat and upbeat outlook, its stock has suffered with other drug makers.

bearishEndo downgraded at RBC

May 6, 2016 | 7:42 AM EDT

ENDP was downgraded from Outperform to Sector Perform, RBC Capital said. $26 price target. Turnaround is going to take longer than expected. 

By

Carleton English

 | May 5, 2016 | 6:48 PM EDT

The specialty pharmaceutical company gave investors a lot of news to digest -- and they fled.

By

James Passeri

 | Feb 29, 2016 | 5:07 PM EST

the Sale of ASTORA Women's Health could bode well for the speciality pharma, as legal woes persist.

By

Bret Jensen

 | Jan 7, 2016 | 12:00 PM EST

Mylan and Endo International look like bargains at current prices.

By

Bret Jensen

 | Dec 24, 2015 | 1:00 PM EST

These biotech/pharma picks could give you a very happy new year.

By

Bret Jensen

 | Nov 20, 2015 | 9:00 AM EST

The company cleared an important hurdle last month.

bearishEndo cut from Conviction Buy List at Goldman

Oct 26, 2015 | 7:40 AM EDT

ENDP was removed from the Conviction Buy list, according to Goldman Sachs. $84 price target. Company is leveraged to sector headwinds. 

bearishEndo downgraded at Morgan Stanley

Sep 1, 2015 | 6:43 AM EDT

ENDP was downgraded from Overweight to Equal-weight, Morgan Stanley said. $85 price target. Company has limited long-term growth visibility. 

bullishEndo upgraded at RBC

Jul 17, 2015 | 7:11 AM EDT

ENDP was upgraded from Outperform to Top Pick, RBC Capital said. $107 price target. Company is attractively valued and consensus numbers appear too low. 

We knew what the trading world was looking at in recent weeks.  It was the famous head an...
I've already posted this on twitter.  This is just a reminder that even though AAPL is ra...
Under Armour (UA) is getting lots of press today after signing "The largest revenue contra...
FIBOCALL: XLF- Are you a BUYER today? The XLF is flirting with the 100 Week Moving Average...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.